Results 41 to 50 of about 1,669 (70)

L-DOPA neurotoxicity is mediated by up-regulation of DMT1-IRE expression.

PLoS ONE, 2009
BackgroundThe mechanisms underlying neurotoxicity caused by L-DOPA are not yet completely known. Based on recent findings, we speculated that the increased expression of divalent metal transporter 1 without iron-response element (DMT1-IRE) induced by L ...
Fang Du, Zhong-ming Qian, Li Zhu, Xiao Mei Wu, Wing-ho Yung, Ting-yuk Tsim, Ya Ke   +6 more
doaj   +1 more source

l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease

Frontiers in Pharmacology, 2019
l-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective therapeutic agent for Parkinson’s disease (PD). l-DOPA is traditionally believed to be an inert amino acid that exerts actions and effectiveness in PD through its conversion to dopamine.
Yoshio Goshima, Daiki Masukawa, Yuka Kasahara, Tatsuo Hashimoto, Aderemi Caleb Aladeokin   +4 more
doaj   +1 more source

Analysis of amino acids in Mucuna pruriens supplements using hydrophilic interaction liquid chromatography-tandem mass spectrometry

Amino Acids
Mucuna pruriens (MP), or velvet bean, has been used as an alternative medicine in India for over 4500 years, predominantly due to the natural abundance of the non-protein amino acid L-3,4-dihydroxyphenylalanine (L-DOPA).
Connor R. Phillips, Jake P. Violi, David P. Bishop, Kenneth J. Rodgers   +3 more
doaj   +1 more source

Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease

Neurobiology of Disease, 2009
Development of L-DOPA-induced dyskinesia (LID) remains a major problem in the long-term treatment of Parkinson's disease (PD). Sensitization to L-DOPA correlates with ectopic expression of D3 dopamine receptors in the striatum, implicating D3 receptors ...
Naomi P. Visanji, Susan H. Fox, Tom Johnston, Gabriela Reyes, Mark J. Millan, Jonathan M. Brotchie   +5 more
doaj   +1 more source

Management of L-dopa overdose in the competitive inhibition state

Drug, Healthcare and Patient Safety, 2014
Marty Hinz,1 Alvin Stein,2 Ted Cole3 1Clinical Research, NeuroResearch Clinics, Inc., Cape Coral, FL, USA; 2Stein Orthopedic Associates, Plantation, FL, USA; 3Cole Center for Healing, Cincinnati, OH, USA Abstract: The amino acid L-3,4 ...
Hinz M, Stein A, Cole T
doaj  

THE INFLUENCE OF INTERMITTENT L-DOPA TREATMENT ONSTRIATAL MOLECULAR MARKERS IN HEMIPARKINSONIANRATS*

Zdravniški Vestnik, 2008
Motor complications after chronic l-DOPA treatment in patients with Parkinson’s diseasemay be caused by the fluctuations of l-DOPA availability in the brain that provokes thesensitization of striatal output neurons of dopamine-depleted striatum.
Gordana Glavan, Marko Živin
doaj  

L-Dopa-modified microtubules lead to synapse instability in cultured neurons: possible implications in Parkinson’s disease therapy

npj Parkinson's Disease
L-Dopa, the main Parkinson’s disease treatment, unexpectedly alters the postsynaptic architecture of cultured mouse neurons through its incorporation into α-tubulin via tubulin tyrosine ligase (TTL).
Agustina Zorgniotti, Aditi Sharma, Sacnicte Ramirez-Rios, Chadni Sanyal, Martina Aleman, Yanina Ditamo, Marie-Jo Moutin, C. Gastón Bisig, Leticia Peris   +8 more
doaj   +1 more source

Levodopa is associated with reduced development of new-onset geographic atrophy in patients with age-related macular degeneration

Eye and Vision
Background Geographic atrophy (GA) is a significant cause of vision loss in patients with age-related macular degeneration (AMD). Current treatments are limited to anti-complement drugs, which have limited efficacy to delay progression with significant ...
Kyle S. Chan, Nitika Aggarwal, Shannon Lawson, Nick Boucher, Mathew W. MacCumber, Jeremy A. Lavine   +5 more
doaj   +1 more source

Lack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats

Brazilian Journal of Medical and Biological Research, 2010
7-Nitroindazole (7-NI) inhibits neuronal nitric oxide synthase in vivo and reduces l-DOPA-induced dyskinesias in a rat model of parkinsonism. The aim of the present study was to determine if the anti-dyskinetic effect of 7-NI was subject to tolerance ...
N. Novaretti, F.E. Padovan-Neto, V. Tumas, C.A. da-Silva, E.A. Del Bel   +4 more
doaj  

The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats

Drug Design, Development and Therapy, 2014
Lu Song,* Xinxin Yang,* Yaping Ma, Na Wu, Zhenguo Liu Department of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, People’s Republic of China *These authors contributed equally to this work Abstract: The ...
Song L, Yang X, Ma Y, Wu N, Liu Z
doaj